Parkin deficiency modulates NLRP3 inflammasome activation by attenuating an A20‐dependent negative feedback loop. Issue 8 (17th April 2018)

• Record Type: Journal Article
• Authors: Mouton‐Liger, François; Rosazza, Thibault; Sepulveda‐Diaz, Julia; Ieang, Amélie; Hassoun, Sidi‐Mohamed; Claire, Emilie; Mangone, Graziella; Brice, Alexis; Michel, Patrick P.; Corvol, Jean‐Christophe; Corti, Olga
• Is Part Of: Glia. Volume 66:Issue 8(2018)
• Page Start: 1736
• Page End: 1751
• Publication Date: 2018-04-17
• Subjects: human macrophages -- neuroinflammation -- NLRP3‐inflammasome -- Parkin -- Parkinson's disease -- primary microglia; Neuroglia -- Periodicals; Neurology -- Periodicals; 611.0188
• DOI: 10.1002/glia.23337
• Languages: English
• ISSNs: 0894-1491

Abstract

Abstract: Neuroinflammation and mitochondrial dysfunction, key mechanisms in the pathogenesis of Parkinson's disease (PD), are usually explored independently. Loss‐of‐function mutations of PARK2 and PARK6, encoding the E3 ubiquitin protein ligase Parkin and the mitochondrial serine/threonine kinase PINK1, account for a large proportion of cases of autosomal recessive early‐onset PD. PINK1 and Parkin regulate mitochondrial quality control and have been linked to the modulation of innate immunity pathways. We report here an exacerbation of NLRP3 inflammasome activation by specific inducers in microglia and bone marrow‐derived macrophages from Park2 −/− and Pink1 −/− mice. The caspase 1‐dependent release of IL‐1β and IL‐18 was, therefore, enhanced in Park2 −/− and Pink1 −/− cells. This defect was confirmed in blood‐derived macrophages from patients with PARK2 mutations and was reversed by MCC950, which specifically inhibits NLRP3 inflammasome complex formation. Enhanced NLRP3 signaling in Parkin‐deficient cells was accompanied by a lack of induction of A20, a well‐known negative regulator of the NF‐κB pathway recently shown to attenuate NLRP3 inflammasome activity. We also found an inverse correlation between A20 abundance and IL‐1β release, in human macrophages challenged with NLRP3 inflammasome inducers. Overall, our observations suggest that the A20/NLRP3‐inflammasome axis participates in the pathogenesis of PARK2 ‐linked PD, paving the way for the exploration of its potential as a biomarker and treatment target. Main Points: Parkin deficiency exacerbates the NLRP3 inflammasome by disrupting A20‐dependent negative regulation. NLRP3 inflammasome overactivation and A20 deregulation were also observed in blood‐derived macrophages from patients with PARK2 mutations.